IONS news, real time IONS stock news, Ionis Pharmaceuticals news today

News

IONS

81.68

-0.16%

-0.13

How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors

Simply Wall St · 1h ago

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

NASDAQ · 2d ago

What Does the Market Think About Ionis Pharmaceuticals Inc?

Benzinga · 2d ago

Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares

Reuters · 2d ago

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga · 3d ago

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS)

TipRanks · 3d ago

Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships

TipRanks · 3d ago

Ionis gets FDA breakthrough therapy status for zilganersen

Seeking Alpha · 4d ago

Ionis Pharma: FDA Grants Breakthrough Therapy Designation To Zilganersen

NASDAQ · 4d ago

Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen

TipRanks · 4d ago

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Reuters · 4d ago

IONIS PHARMACEUTICALS INC - ON TRACK TO SUBMIT NDA FOR ZILGANERSEN IN Q1 2026

Reuters · 4d ago

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Barchart · 4d ago

Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen

Simply Wall St · 5d ago

Ionis Wins FDA Breakthrough Therapy Designation For Olezarsen In Severe Hypertriglyceridemia

NASDAQ · 5d ago

IONIS PHARMACEUTICALS SHARES REVERSE PREMARKET COURSE, LAST DOWN 2.4%

Reuters · 5d ago

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA)

TipRanks · 5d ago

IONIS PHARMACEUTICALS SHARES UP 3.5% PREMARKET AFTER CO RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR OLEZARSEN FOR SHTG

Reuters · 5d ago

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Olezarsen for Severe Hypertriglyceridemia

Reuters · 5d ago

IONIS PHARMACEUTICALS INC: ON TRACK TO SUBMIT SUPPLEMENTAL NEW DRUG APPLICATION BY END OF YEAR

Reuters · 5d ago

Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.

About IONS

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.